Free Consultations 24/7
Mainstream and social media coverage have created a surge in the usage of injectable type 2 diabetes medications, such as Ozempic® and Rybelsus®, for weight loss purposes.
While these glucagon-like peptide-1 (GLP-1) agonists were originally formulated to assist type 2 diabetes patients in regulating their blood sugar levels, they have recently emerged as effective tools for weight reduction. This unforeseen benefit has led medical practitioners to prescribe them off-label for weight loss, alongside another GLP-1 agonist named Wegovy®, which is designed and prescribed exclusively for weight loss.
The positive impact of GLP-1 agonists on weight loss comes with serious drawbacks for many patients. These drugs are associated with many severe health complications, including:
If you or a loved one used a GLP-1 agonist like Ozempic®, Wegovy®, or Rybelsus® for at least 30 days, and subsequently experienced any of the complications or health issues listed above, our legal team wants to speak with you. We’re working hard to assist victims who were harmed by GLP-1 agonists, and it’s our goal to help you get the compensation you deserve for your medical bills, lost wages, and pain and suffering.
GLP-1 agonists contribute to weight loss by slowing the pace at which the stomach processes food. Because food stays in their stomachs longer, people who take these medications feel full for longer periods of time, leading to reduced caloric intake and eventual weight reduction. However, this delayed stomach emptying can yield severe complications for certain individuals.
The most prevalent side effects associated with Ozempic® include nausea, abdominal discomfort, constipation, diarrhea, and vomiting. While these effects are transient and mild for some individuals, they can be chronic and severe in other patients.
In addition to enduring severe and chronic stomach-related distress, GLP-1 agonists have the potential to trigger gastroparesis (stomach paralysis), a distressing condition that may trigger malnourishment, dehydration, gastroesophageal reflux disease (GERD), and other complications.
The precise mechanisms underlying how GLP-1 agonists cause damage, injury, and failure of various organs is still unclear based on current evidence. However, reports suggest these medications heighten the risk of or induce organ complications in some individuals:
The complications associated with GLP-1 agonists, such as Ozempic®, Rybelsus®, and Wegovy®, extend beyond mere discomfort for some patients—they can be potentially fatal.
We believe the manufacturers of these medications failed to adequately warn patients about potential complications. When patients aren’t told of the potential dangers they face from taking medications—especially when those dangers have the potential to be severe—they should be compensated for any and all injuries and complications they suffer.
Don’t wait another minute to get experienced and determined legal representation on your side. Get in touch with our legal team today for a case review and to get started on the case that can help you get maximum compensation.